Exosome Diagnostics, Life Technologies Ink Agreement for Oncology Dx Program | GenomeWeb

NEW YORK (GenomeWeb News) – Exosome Diagnostics today said that it has signed an agreement with Life Technologies to use the Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument for its exosome biofluid in vitro diagnostics program.

Exosome will validate the 7500 platform with exosome biofluid RNA isolation kits in clinical trials beginning this year in brain and prostate cancer. Terms of the alliance were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.